Skip to main content
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. — Investor Relations & Filings

Ticker · ALLO ISIN · US0197701065 US Manufacturing
Open in API
Filings indexed 523 across all filing types
Latest filing 2020-06-09 Director's Dealing
Country US United States of America
Listing US ALLO

About Allogene Therapeutics, Inc.

https://allogene.com/

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies. The company engineers T cells from healthy donors to create "off-the-shelf" treatments for cancer and autoimmune diseases. This approach is designed to enable on-demand availability, scalability, and reliability, contrasting with autologous therapies that use a patient's own cells. Allogene's pipeline utilizes multiplex gene-engineering and gene-editing capabilities. Its key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for clear cell renal cell carcinoma, and ALLO-329 for autoimmune disease.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2020-06-09 English
PRIMARY DOCUMENT
Director's Dealing
2020-06-09 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-06-05 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 1, 2020, reporting the entry into an underwriting agreement for a public offering of common stock. It details the terms of the offering, the parties involved, and the gross proceeds. The document includes exhibits such as the underwriting agreement and legal opinions, and press releases announcing the offering commencement and pricing. There are no financial statements or comprehensive financial data presented, only an announcement of a financing event. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other filing types. The document length is over 6000 characters, so it is not a mere announcement of a report publication (RPA). Therefore, the correct classification is CAP with high confidence.
2020-06-04 English
PRIMARY DOCUMENT
Director's Dealing
2020-06-04 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement and prospectus related to a public offering of common stock by Allogene Therapeutics, Inc. It includes information about the offering size, pricing, underwriting, risk factors, company overview, clinical trial updates, and use of proceeds. The document is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing under the Securities Act of 1933. The content focuses on capital raising through a stock offering and includes detailed terms and conditions of the offering, underwriting arrangements, and related disclosures. This type of document is best classified as a Capital/Financing Update (CAP) because it provides updates on the company's fundraising activities and capital structure changes. It is not an annual or quarterly report, earnings release, or any other category related to financial results or governance. The length and detail confirm it is not a mere announcement but the actual offering document.
2020-06-03 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.